Posted on October 5th, 2011 by
Among men with metastatic, hormone-refractory prostate cancer that has previously been treated with Taxotere® (docetaxel), Zytiga® (abiraterone) reduced fatigue in addition to improving overall survival. These results were presented at the 2011 European Multidisciplinary Cancer Congress.
Prostate cancer is a hormonally sensitive disease that can often be controlled for long periods with androgen-deprivation therapy (ADT). When prostate cancer stops responding to this treatment, it is referred to as hormone-refractory prostate cancer. Metastatic hormone-refractory prostate cancer is a challenging form of the disease to treat because the cancer has spread to distant sites in the body and does not respond to treatment with standard hormonal therapy.
Zytiga, which is taken orally, blocks the production of androgens (male hormones such as testosterone) not only by the testes but also by the adrenal glands and the tumor itself. Zytiga was approved in combination with prednisone for the treatment of metastatic, hormone-refractory prostate cancer that has previously been treated with chemotherapy. In these patients, the combination of Zytiga and prednisone resulted in better overall survival than prednisone alone.
To assess how Zytiga affects fatigue—a common and potentially debilitating problem among men with advanced prostate cancer—researchers evaluated information from one of the Zytiga clinical trials. Information was available about 797 men who had been treated with Zytiga plus prednisone and 398 men who had been treated with prednisone alone. The two groups of men had similar fatigue scores at the start of the study.
Fatigue is a common problem among patients with advanced cancer and can have a profound effect on quality of life. The results of this analysis suggest that in addition to improving overall survival, Zytiga may also help to reduce fatigue among men with advanced prostate cancer.
Reference: Sternberg CN, Scher HI, Molina A et al. Fatigue improvement/reduction with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel – results from the COU-AA-301 phase 3 study. Presented at the 2011 European Multidisciplinary Cancer Conference. Stockholm, Sweden. September 23-27, 2011. Abstract 7015.
Copyright © 2011 CancerConsultants. All Rights Reserved.
You must be logged-in to the site to post a comment.